Phase 1 N=53 RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
Covid19
Primary: Total Protein Normal to Abnormal Transition — 4.5; 4.6 percentage of participants — p=1.000
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=34 A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Squamous Cell Carcinoma of Head and Neck
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity — 4; 2; 4; 3 Participants
Phase 1 N=40 Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
Ovarian Carcinoma · Soft Tissue Sarcoma
Primary: Dose Escalation Part: Establish the Recommended Phase II Dose (RP2D), the Maximum Tolerated Dose (MTD) Evaluated on the First Cycle (D1 to D21), the Safety Profile, and…
Phase 1 N=60 Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
Malaria
Primary: Number of Participants With Solicited Local Reactions — 0; 1; 1; 0 Participants
Phase 1 N=14 Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞) — 288.55; 105.8 μg·h/L/mg
Phase 1 N=28 A Study in Healthy People to Compare Two Different Sifrol® Tablets
Healthy
Primary: Area Under the Concentration-time Curve of Pramipexole in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 3573; 3632 hour * picogram…
Phase 1 N=36 Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
Glioblastoma
Primary: Safety of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex in Subjects With Recurrent or Progressive Glioblastoma Based on Evaluation of Adverse Events Summarized by…
Phase 1 N=32 A Study of RGLS8429 in Healthy Volunteers
Healthy Volunteers
Primary: Incidence of Adverse Events (AEs) — 0; 0; 0; 0 participants
Phase 1 N=28 A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
Obesity
Primary: Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) — 0.0; 83.3; 0.0; 85.7 Percentage of participants
Phase 1 N=42 Phase 1 Study of SAR440894 vs Placebo
Chikungunya Virus Infection
Primary: Frequency of Adverse Events (AEs) — 5; 3; 2; 3 Participants
Phase 1 N=29 ED Initiated Oral Naltrexone for AUD
Alcohol Use Disorder
Primary: Number of Participants Enrolled and Receiving Formal Addiction Treatment at Day 14 — 6; 15 Participants
Phase 1 N=20 A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age
Tuberculosis
Primary: Area Under the Plasma Drug Concentration (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) After a Single Dose of EE and LNG — 627.11; 552.01; 24651.76…
Phase 1 N=32 Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers
Anemia, Iron Deficiency
Primary: Ratio of Maximum Serum Concentration (Cmax) of Total Iron in Fasted Condition — 69.94 ratio
Phase 1 N=39 A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321
Healthy
Primary: Number of Subjects With Drug-related Adverse Events — 0; 1; 0; 0 Participants
Phase 1 N=18 Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART
HIV Vaccine · HIV-1-infection
Primary: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) — 12.5; 0; 0 percentage of participants